文献速递胃肠动力与功能性疾病

随机临床试验:利福昔明对比安慰剂治疗功能性消化不良

Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia.
PubMed 文献 · Aliment Pharmacol Ther · 2017-01-23

这项双盲、随机、安慰剂对照试验纳入86例符合罗马III标准的功能性消化不良患者,利福昔明400mg或安慰剂每日三次共2周,随访8周。第8周利福昔明组总体消化不良症状充分缓解率显著高于安慰剂组(78% vs 52%,P=0.02),女性亚组反应更明显,两组不良反应发生率相似。

要点

  • 利福昔明400mg每日三次共2周,第8周总体症状充分缓解率78% vs 安慰剂52%(P=0.02)。
  • 第4周利福昔明在嗳气和餐后饱胀/腹胀的充分缓解上优于安慰剂。
  • 女性亚组第4周缓解率76% vs 42%(P=0.006),第8周79% vs 47%(P=0.008)。

核心结论

  • 2周利福昔明治疗使功能性消化不良患者总体消化不良症状、嗳气和餐后饱胀/腹胀获得充分缓解,女性中差异更明显。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,连续纳入符合罗马III标准的功能性消化不良患者86例,随机接受利福昔明400mg或安慰剂每日三次共2周,随访8周。

主要发现

  • 第8周利福昔明组总体消化不良症状充分缓解率78% vs 安慰剂组52%(P=0.02)。
  • 第4周利福昔明在嗳气和餐后饱胀/腹胀的充分缓解上优于安慰剂。
  • 女性亚组第4周总体症状充分缓解率76% vs 42%(P=0.006),第8周79% vs 47%(P=0.008),第4周嗳气和餐后饱胀/腹胀亦有改善。
  • 两组不良反应发生率相似。

关键数值与推荐

  • 主要终点为总体消化不良症状充分缓解;次要终点为各单项消化不良症状缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gut dysbiosis may contribute to pain and bloating in patients with functional gastrointestinal disease. AIMS: To determine if treatment with rifaximin would improve the symptoms of functional dyspepsia in Chinese patients in a double-blinded, randomised, placebo-controlled trial. METHODS: Consecutive subjects with a diagnosis of functional dyspepsia as per the Rome III criteria were randomised to receive rifaximin 400 mg or placebo, all taken three times daily for 2 weeks. The investigators and study subjects were blinded to the treatment allocation. Subjects were followed up for 8 weeks. The primary end point was adequate relief of global dyspeptic symptoms (GDS). Secondary endpoints were relief of individual dyspeptic symptoms. RESULTS: Eighty-six subjects were recruited. At week 8, there were significantly more subjects in the rifaximin than in the placebo group who experienced adequate relief of GDS (78% vs. 52%, P = 0.02). A trend favouring rifaximin group was also noted in the preceding 4 weeks. Rifaximin was also superior to placebo in providing adequate relief of belching and post-prandial fullness/bloating (PPF) in subjects at week 4. Subgroup analysis revealed that female subjects had more significant response to rifaximin treatment (adequate relief of GDS at week 4: 76% vs. 42%, P = 0.006; week 8: 79% vs. 47%, P = 0.008), as well as improvements in their belching and PPF at week 4. The incidences of adverse effects were similar in both groups. CONCLUSIONS: Treatment with 2 weeks of rifaximin led to adequate relief of global dyspeptic symptoms, belching and post-prandial fullness/bloating in subjects with functional dyspepsia. The difference was more marked in females. (clinicaltrials.org NCT01643083).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tan VP, Liu KS, Lam FY, et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2017. PMID: 28112426. doi:10.1111/apt.13945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。